Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papi...(. Some of the risksuncertainties and ass...)

Date:5/28/2008

. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to: (i) the risk that our APTIMA HPV Assay will perform poorly in its US clinical trial, (ii) the risk that the APTIMA HPV Assay will not be cleared for marketing in the US in the timeframe we expect, if at all, (iii) the possibility that the market for the sale of our APTIMA HPV Assay may not develop as expected, (iv) we may not be able to compete effectively with other companies already selling HPV diagnostic products or which launch such products in the future, (v) we depend on a small number of contract manufacturers and single source suppliers of raw materials, (vi) changes in third-party reimbursement policies regarding our products could adversely affect their sales, (vii) changes in government regulation affecting our products could harm our sales and increase our development costs, and (viii) litigation involving the assertion of third party patent rights could be expensive and divert management's attention, and/or result in damages or injunctive relief. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Michael Watts

Senior director, investor relations

and corporate communications

858-410-8673 Available Topic Expert(s): For information on the
'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
2. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
3. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
4. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
5. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
7. Carl Hull Named President and Chief Operating Officer of Gen-Probe
8. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
9. Gen-Probe to Webcast Three Upcoming Presentations
10. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
11. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference